Loading…
Anavex Life Sciences Corp. is projected to rise to $2.54 by 2027, a +2% move from its current price of $2.50. AVXL is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.42 | $2.50 | $2.59 | +0.03% |
| Jul 14 | $2.39 | $2.50 | $2.62 | +0.06% |
| Jul 15 | $2.36 | $2.50 | $2.65 | +0.09% |
| Jul 16 | $2.34 | $2.50 | $2.68 | +0.13% |
| Jul 17 | $2.32 | $2.50 | $2.70 | +0.16% |
| Jul 18 | $2.31 | $2.50 | $2.72 | +0.19% |
| Jul 19 | $2.29 | $2.51 | $2.74 | +0.22% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.29 | $2.51 | $2.74 | +0.22% |
| Week 2 | $2.21 | $2.51 | $2.85 | +0.44% |
| Week 3 | $2.16 | $2.52 | $2.94 | +0.66% |
| Week 4 | $2.11 | $2.52 | $3.01 | +0.88% |
| Week 5 | $2.07 | $2.53 | $3.08 | +1.11% |
| Week 6 | $2.04 | $2.53 | $3.15 | +1.33% |
| Week 7 | $2.01 | $2.54 | $3.21 | +1.55% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Anavex Life Sciences Corp. is a biopharmaceutical company focused on developing treatments for central nervous system (CNS) disorders. It operates in the Healthcare sector and was incorporated in 2004, with headquarters in New York, New York.
The company’s pipeline includes ANAVEX 2-73 (blarcamesine), its lead drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. It has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer’s disease, a Phase 2 proof-of-concept study in Parkinson’s disease dementia, and a Phase 2 and a Phase 3 study in Rett syndrome. Its ANAVEX 3-71 targets SIGMAR1 and M1 muscarinic receptors and is described as demonstrating disease-modifying activity against Alzheimer’s disease in transgenic mice.
Anavex Life Sciences’ focus on CNS disorders includes Rett syndrome and other CNS conditions, with development efforts spanning Alzheimer’s, Parkinson’s, schizophrenia, neurodevelopmental and neurodegenerative diseases, rare diseases, pain, and various types of cancer.
Anavex Life Sciences Corp. (AVXL) is publicly traded with a current price of $2.50 and a market capitalization of $231.68M, ranking 3691 by market cap.
In the near term, the stock trades within a 30-day range of $2.00 to $3.12, with a near-term support level at $2.46 and a resistance level at $3.03.
Technical indicators show a neutral tone: RSI(14) at 40, SMA50 at $2.81, SMA200 at $4.55, and an implied annualized volatility of 60%.
A major floor 16.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.6% away) — a key level to hold.
The nearest ceiling, 21.2% above — a clean break opens room to run.
A major ceiling 100.0% above — clearing it would confirm fresh momentum.
Key AVXL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AVXL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.65 | Sell | $2.62 | Sell |
| MA 10 | $2.64 | Sell | $2.63 | Sell |
| MA 20 | $2.60 | Sell | $2.64 | Sell |
| MA 50 | $2.81 | Sell | $2.84 | Sell |
| MA 100 | $3.32 | Sell | $3.35 | Sell |
| MA 200 | $4.55 | Sell | $4.45 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.60 | Neutral |
| Stoch RSI (14) | 18.19 | Buy |
| CCI (20) | -87.44 | Neutral |
| Williams %R (14) | -88.14 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -3.10 | Sell |
| Bollinger %B (20,2) | 0.22 | Neutral |
| Stochastic %K (14) | 11.86 | Buy |
| TRIX (15) | -0.31 | Sell |
| Awesome (5,34) | -0.00 | Sell |
| Ultimate (7,14,28) | 40.69 | Neutral |
| Momentum (10) | 0.04 | Buy |
| Aroon Osc (25) | -16.00 | Sell |
| Hull MA (9) | 2.66 | Sell |
| ADX (14) | 12.66 | Neutral |
| ATR (14) | 0.08 | Info |
The 30-day technical picture is neutral, with price action constrained between support and resistance levels. RSI sits at 40, pointing to modest momentum and room for movement before overbought conditions might emerge.
The near-term setup shows the stock hovering near the $2.46 support, while the 50-day moving average is at $2.81, suggesting a potential test of resistance near $3.03 if buyers regain tempo. The 30-day price range extends from $2.00 to $3.12, highlighting limited upside in the immediate horizon unless catalysts arise.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.46 | $2.50 | $3.21 | 0% | Neutral | |
| $1.98 | $2.54 | $3.47 | +2% | Neutral | |
| $1.97 | $2.61 | $3.73 | +5% | Neutral | |
| $1.95 | $2.67 | $3.95 | +7% | Neutral | |
| $2.02 | $2.85 | $4.33 | +14% | Neutral | |
| $2.51 | $3.61 | $5.64 | +45% | Bullish | |
| $2.68 | $3.95 | $6.30 | +58% | Bullish | |
| $2.69 | $4.04 | $6.58 | +62% | Bullish | |
| $2.63 | $4.03 | $6.68 | +61% | Bullish | |
| $2.42 | $3.78 | $6.37 | +51% | Bullish | |
| $3.52 | $6.02 | $10.89 | +141% | Bullish | |
| $6.17 | $12.35 | $24.79 | +394% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.46 | $2.50 | $3.01 | +0.00% |
| August 2026 | $2.10 | $2.49 | $3.05 | -0.21% |
| September 2026 | $2.15 | $2.57 | $3.19 | +3.12% |
| October 2026 | $2.18 | $2.63 | $3.30 | +2.26% |
| November 2026 | $2.10 | $2.55 | $3.23 | -2.93% |
| December 2026 | $2.06 | $2.51 | $3.21 | -1.66% |
Click any year to see its month-by-month AVXL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect AVXL to range from $2.46 to $3.21 through 2026. The $2.50 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The AVXL price prediction for 2027 points to an average of $2.54 (low $1.98, high $3.47) — a potential gain of +2% on today's $2.50. A consolidation phase looks the most probable path here.
In 2028, AVXL is projected to trade between $1.97 and $3.73, averaging $2.61 — a potential gain of +5% from today's $2.50. That is up +3% on the projected 2027 average. Price action looks broadly range-bound.
Anavex Life Sciences Corp.'s 2029 outlook centres on $2.67, within a $1.95 to $3.95 range. That is up +2% on the projected 2028 average. That marks a +7% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, AVXL could reach as high as $4.33, with a base case around $2.85 and support toward $2.02 — roughly +14% from $2.50. Price action looks broadly range-bound.
Expect AVXL to range from $2.51 to $5.64 through 2031. The $3.61 average target implies a +45% move from current prices. That is up +27% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The AVXL price prediction for 2032 points to an average of $3.95 (low $2.68, high $6.30) — a potential gain of +58% on today's $2.50. Momentum favours further upside here.
In 2033, AVXL is projected to trade between $2.69 and $6.58, averaging $4.04 — a potential gain of +62% from today's $2.50. That is up +2% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Anavex Life Sciences Corp.'s 2034 outlook centres on $4.03, within a $2.63 to $6.68 range. That is 0% versus the projected 2033 average. That marks a +61% change versus current levels. Momentum favours further upside here.
By 2035, AVXL could reach as high as $6.37, with a base case around $3.78 and support toward $2.42 — roughly +51% from $2.50. Buyers look set to stay in control over this stretch.
Expect AVXL to range from $3.52 to $10.89 through 2040. The $6.02 average target implies a +141% move from current prices. That is up +59% on the projected 2035 average. Momentum favours further upside here.
The AVXL price prediction for 2050 points to an average of $12.35 (low $6.17, high $24.79) — a potential gain of +394% on today's $2.50. Buyers look set to stay in control over this stretch.
Investing $1,000 in AVXL today (≈ 400 AVXL) could be worth
$4,941.38
+$3,941.38 (+394%) by 2050 · US Dollar
Based on the average projected AVXL price of $12.35 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AVXLwould be worth at today's price.
$1,000 invested in AVXL on Jul 10, 2025 (≈ 89.445436 AVXL) would be worth
$223.61
-$776.39 (-77.6%) today · 0.22× · US Dollar
Based on a AVXL entry price of $11.18 vs. today's $2.5.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.76 | $905.8 | -9.4% |
| 1 month ago | $2.46 | $1,016.26 | +1.6% |
| 3 months ago | $2.95 | $847.46 | -15.3% |
| 6 months ago | $4.29 | $582.75 | -41.7% |
| 1 year ago | $11.18 | $223.61 | -77.6% |
| All time (5.0y) ago | $25.4 | $98.43 | -90.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AVXL forecast.
Our base-case forecast reaches $5.00 around 2040.
Implied market cap at $5.00: $463.36M
The multi-year forecast depicts a climb in average price and substantial upside into the 2040s and 2050. In 2026 the average price is projected at $2.50 with a minimum of $2.46 and a maximum of $3.21, yielding a 0 ROI in that year. By 2030, the average is forecast at $2.85 with a range of $2.03 to $4.33 and an ROI of 13.9, maintaining a neutral sentiment.
From 2031 onward the outlook becomes more bullish: 2031 (avg $3.61, min $2.51, max $5.63, ROI 44.4), 2032 (avg $3.95, min $2.69, max $6.31, ROI 58.2), 2033 (avg $4.04, min $2.69, max $6.57, ROI 61.6), 2034 (avg $4.02, min $2.62, max $6.67, ROI 61), and 2035 (avg $3.78, min $2.42, max $6.38, ROI 51.3).
The bullish trend continues to 2040, where the average price is projected at $6.01 with a range of $3.52 to $10.89 and an ROI of 140.5. By 2050, the average price could reach $12.36 with a range of $6.18 to $24.81 and an ROI of 394.6, supported by a bullish sentiment across these years.
These are estimates, not guarantees, and depend on market conditions and clinical and regulatory outcomes. The forecast shows meaningful upside potential over the long term but also considerable uncertainty in the near term.
Tap a question to reveal the answer.
Avg $2.85; Min $2.03; Max $4.33; ROI 13.9; Sentiment NEUTRAL. Note: These are estimates and not guarantees.
Yes, the 2040 forecast lists a max of $10.89 with an average of $6.01 and a min of $3.52; ROI 140.5; Sentiment BULLISH.
From 2031 onward, the forecast shows BULLISH sentiment with rising averages (e.g., 2031 avg $3.61, 2032 $3.95, 2033 $4.04, 2034 $4.02, 2035 $3.78) and high ROI potential (up to 61.6 in 2033 and 140.5 by 2040, 394.6 by 2050). These are estimates, not guarantees.
Current price $2.50; Market cap $231.68M.
Avg $12.36; Min $6.18; Max $24.81; ROI 394.6; Sentiment BULLISH. Note: These are forecasts, not guarantees.
Anavex Life Sciences Corp. Community Discussion
0Share your Anavex Life Sciences Corp. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.